Cyclosporin A has no impact on alterations of the lipid profile after renal transplantation

  • J. Rosman
  • D. Evequoz
  • G. Thiel
  • J. Landmann
Conference paper

Abstract

The literature contains conflicting ideas regarding the role of cyclosporin A (CyA) in the induction of posttransplant dyslipidemia. The available studies contain small numbers of patients, especially on CyA monotherapy. We compared 65 patients on conventional azathioprine-prednisone therapy (AP) with 85 patients on CyA monotherapy, 19 on CyA-azathioprine therapy (CA), 20 on CyA-prednisone therapy (CP), and 52 on a triple therapy with CyA, azathioprine, and prednisone (CAP). From the results, it is concluded that patients on CyA monotherapy had lower serum cholesterol levels, with a lower high-density lipoprotein (HDL)-cholesterol level, probably due to the lower total cholesterol, compared with AP patients. From all groups, the CyA monotherapy group showed the most beneficial lipid profile. No additive negative influences of CyA when combined with other immunosuppressive drugs were noted. Thus, a correlation between derangements of the lipid profile and CyA therapy could not be confirmed. Further analysis of our data showed negative influences of antihypertensive treatment on lipid metabolism, particularly in the case of treatment with β-blockers or diuretics. It cannot be excluded that studies showing a negative influence of CyA therapy on lipid homeostasis were biased by secondary factors like antihypertensive therapy, which was often not taken into account.

Key words

Transplantation Cyclosporin A Lipids Antihypertensive drugs Insulin sensitivity Immunosuppression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262:53–56PubMedCrossRefGoogle Scholar
  2. 2.
    Bittar AE, Ratcliffe PJ, Richardson AJ, Raine AE, Jones L, Yudkin PL, Carter R, Mann JI, Morris PJ (1990) The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy. Transplantation 50:987–992PubMedCrossRefGoogle Scholar
  3. 3.
    Coronary Drug Project Research Group (1987) Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Am J Cardiol 42: 489–498Google Scholar
  4. 4.
    Ekstrand A, Ahonen J, Groenhagen-Riska C, Groop L (1989) Mechanisms of insulin resistance after kidney transplantation. Transplantation 48:563–568PubMedGoogle Scholar
  5. 5.
    Ferrari P, Rosman J, Weidmann P (1991) Antihypertensive agents, serum lipoproteins, and glucose metabolism. Am J Cardiol 67:26B-35BPubMedCrossRefGoogle Scholar
  6. 6.
    Fuhrer JA, Horber FF (1990) Additive effects of prednisone and cyclosporine-A therapy on serum cholesterol in renal transplant patients: effect of time interval after kidney transplantation and therapy with fibrates. J Am Soc Nephrol 1:757Google Scholar
  7. 7.
    Ghosh P, Evans DB, Tomlinson SA, Calne RY (1973) Hyperlipidemia following renal transplantation. Transplantation 15: 521–525PubMedCrossRefGoogle Scholar
  8. 8.
    Hodel K, Mordasini RC, Brunner FP, Thiel G (1986) Cyclosporin A and Hyperlipidaemie nach Nierentransplantation. Schweiz Med Wochenschr 116:885–888PubMedGoogle Scholar
  9. 9.
    Johnson RWG (1986) Cyclosporine in cadaveric renal transplantation: three-year follow-up of a European multicentre trial. Transplant Proc 18:1229–1233Google Scholar
  10. 10.
    Najarian JS (1988) Long term results at the University of Minnesota. Transplant Immunol 4 (4)Google Scholar
  11. 11.
    Rosman J, Weidmann P, Ferrari P (1990) Antihypertensive drugs and serum lipoproteins, J Drug Dev 3 [Suppl 1]: 129–139Google Scholar
  12. 12.
    Traindl O, Reading S, Franz M, Pohanka E, Pidlich J, Kovarik J (1991) Cyclosporin-A does not cause hyperlipidemia in kidney graft recipients. Clin Transplant 5:265–267Google Scholar
  13. 13.
    Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Dunn J, Goldstein RA, Buren CT, van-Lewis RM, Kahan BD (1989) Lipid abnormalities in renal transplant recipients treated with cyclosporine. Transplantation 48:37–43PubMedCrossRefGoogle Scholar
  14. 14.
    Venkateswara Rao K, Andersen R (1988) Long-term results and complications in renal transplant recipients. Transplantation 45: 45–52CrossRefGoogle Scholar
  15. 15.
    Wahlstrom HE, Lavelle-Jones M, Endres D, Akimoto R, Kolter-man O, Moossa AR (1990) Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation 49:600–604PubMedCrossRefGoogle Scholar
  16. 16.
    Wing AJ, Brunner FP, Brynger H, Jacobs C, Kramer P, Selwood NH, Gretz N (1984) Cardiovascular-related causes of death and the fate of patients with renovascular disease. Contrib Nephrol 41:306–311PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. Rosman
    • 1
  • D. Evequoz
    • 1
  • G. Thiel
    • 2
  • J. Landmann
    • 3
  1. 1.Departments of Internal MedicineUniversity Clinic of BasleBasleSwitzerland
  2. 2.Departments of SurgeryUniversity Clinic of BasleBasleSwitzerland
  3. 3.Division of NephrologyUniversity Clinic of BasleBasleSwitzerland

Personalised recommendations